Patent ID: 7138122

Claim:
A therapeutic system comprising a prodrug which is converted to a substantially cytotoxic drug by the action of NQO2, at intracellular sites where NQO2 is expressed, and a compound of formula I wherein R1 is selected from the group consisting of substituted alkyl, including substitution by CONH 2 , OH, halogen, CN, and COOH; aryl; substituted aryl; CONR a R b , where R a and R b are independently H, alkyl, or substituted alkyl, and R 2 and R 3 are independently H, alkyl, or substituted alkyl and R 4 is any of H, alkyl, substituted alkyl, halogen, CN, COOH, CONH 2 , or OH, wherein the compound can pass reducing equivalents to NQO2, in a form for administration to a patient in need thereof, wherein the prodrug is CB 1954.